Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859509 | 0.96 | LMNA (0.40) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL1863287 | 0.72 | KMT2A (0.31) | LMNASMN1; SMN2TP53KMT2A | |
| SCHEMBL1859647 | 0.72 | KMT2A (0.31) | LMNASMN1; SMN2TP53KMT2A | |
| SCHEMBL3590448 | 0.71 | LMNA (0.41) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL3585506 | 0.67 | LMNA (0.37) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL6450378 | 0.66 | LMNA (0.53) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL14473109 | 0.66 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL10878763 | 0.65 | ALDH1A1 (0.56) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL2481405 | 0.65 | ALDH1A1 (0.56) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL3350492 | 0.64 | LMNA (0.51) | LMNASMN1; SMN2USP2HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | LMNA 4104/4885SMN1; SMN2 1477/4885USP2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.